Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)


DMDR, a daunorubicin derivative with a higher therapeutic index and lower cardiotoxicity than either the parent drug or doxorubicin, is active when given PO in experimental animals. We studied its pharmacokinetics in ten patients receiving DMDR IV or PO or IV and PO sequentially at 10–12.5 mg/m2. DMDR and its metabolites were quantified by high-performance… (More)
DOI: 10.1007/BF00306743


9 Figures and Tables

Cite this paper

@article{Lu1986ClinicalPO, title={Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)}, author={Katherine Kun Lu and Niramol Savaraj and John Kavanagh and Lynn G. Feun and Michael Burgess and Gerald Paul Bodey and Ti Li Loo}, journal={Cancer Chemotherapy and Pharmacology}, year={1986}, volume={17}, pages={143-148} }